Clinical trials: Advanced Disease
Prostate Cancer
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
This is a single-center, open-label, non-randomized Phase I study of weekly Cabazitaxel with concurrent intensity modulated radiation therapy (IMRT) (A type of 3-dimensional radiation therapy that uses computer-generated images…
- Trial name
- NCT01420250
- Testing
- Cabazitaxel, Intensity Modulated Radiation Therapy (IMRT), Anti-Androgen Therapy: Bicalutamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
This open-label, single-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer who have completed 4 cycles of standard platinum-based…
- Trial name
- NCT01230710
- Testing
- Erlotinib
- Where
- 7 sites in India
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Family Members, Cancer
Evaluation of FROM-16 in ATMP Patients & Families
Poor health, and its treatment, has impact beyond the healthcare system into wider society. A person's productivity, taxable earnings, benefit payments and community contribution may all be adversely affected by poor health.
- Trial name
- NCT05141318
- Testing
- FROM-16 Questionnaire, Semi-structured two-part interview
- Where
- 5 sites in United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Swansea University
Total Neoadjuvant Treatment, Chemoradiotherapy
Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors
Purpose:To compare the efficacy and the safety of total neoadjuvant chemotherapy + TME with standard neoadjuvant concurrent chemoradiotherapy + TME + adjuvant chemotherapy for locally advanced rectal cancer patients with high…
- Conditions
- Total Neoadjuvant Treatment, Chemoradiotherapy, Local Advanced Rectal Cancer, High Risk Factors
- Trial name
- TNTCRT (NCT03177382)
- Testing
- Total neoadjuvant treatment, concurrent chemoradiotherapy, TME
- Where
- 2 sites in China
- Volunteers
- 458 people
- Sponsor
- West China Hospital
Prostate Cancer
Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer
Prostate cancer is the most common cancer among men in the United States. Through early detection and improved local therapies a large number of men will be cured.
- Trial name
- NCT01417182
- Testing
- 18F-DCFBC
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Small Cell Lung Cancer
Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer
The combination of oxaliplatin and gemcitabine has proven activity in advanced non-small cell lung cancer (NSCLC). Due to its favorable toxicity profile, this combination is optimal for adding new agents.
- Trial name
- NCT00217282
- Testing
- oxaliplatin, gemcitabine, bevacizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mt. Sinai Medical Center, Miami
Liver Cancer
T900607 in Treating Patients With Unresectable Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have unresectable…
- Trial name
- NCT00054262
- Testing
- T900607
- Where
- United States
- Sponsor
- University Hospitals Seidman Cancer Center
Gastrointestinal Neoplasms, Adenocarcinoma
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
The Phase 1b study is an open-label, multicenter dose escalation study designed to assess the safety, tolerability, immunogenicity and recommended phase 2 dose (RP2D) of IMU-131.
- Trial name
- NCT02795988
- Testing
- IMU-131, Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
- Where
- 22 sites in Georgia, India and 5 more
- Volunteers
- 64 people
- Sponsor
- Imugene Limited
EGFR Overexpression, Locally Advanced Solid Tumor
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can…
- Conditions
- EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT06975410
- Testing
- YH32364
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yuhan Corporation
Oral Cancer, Oropharyngeal Cancer
uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer
uPAR PET/CT for Staging Advanced and Localised oral and oropharyngeal cancer
- Conditions
- Oral Cancer, Oropharyngeal Cancer, Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT02960724
- Testing
- 68Ga-NOTA-AE105 PET/CT
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Lymphoma, Non-Hodgkin, Neoplasms
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and…
- Trial name
- NCT02875223
- Testing
- CC-90011, Rifampicin, Itraconazole
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Renal Cell Carcinoma, Renal Cancer
Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer
This is a multicenter, exploratory, prospective study to identify angiogenesis and immune-related biomarkers predictive of progression free survival in patients with metastatic or advanced renal cell carcinoma treated by a…
- Conditions
- Renal Cell Carcinoma, Renal Cancer, Renal Cancer Metastatic
- Trial name
- ANGIOCOR (NCT05285579)
- Testing
- Blood collection, Tumour samples
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer
A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer
This clinical trial is evaluating a drug called AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer.
- Trial name
- NCT05080842
- Testing
- AC682
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Accutar Biotechnology Inc
Carcinoma, Non-small Cell Lung
Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)
This study will use imaging to look at tumor response to erlotinib (Part I) and the combination of erlotinib and dalotuzumab (Part II).
- Trial name
- NCT00729742
- Testing
- Comparator: erlotinib + dalotuzumab, Comparator: erlotinib monotherapy
- Volunteers
- 49 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin plus fluorouracil/leucovorin compared with HAIC of oxaliplatin alone in patients with advanced…
- Trial name
- NCT03812770
- Testing
- Sorafenib, HAIC of FOLFOX, HAIC of OXA
- Where
- 3 sites in China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Non-Hodgkin's Lymphoma, Solid Tumor
Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma
This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetic (PK) of GDC-0349 administered once daily (QD), orally (PO).
- Trial name
- NCT01356173
- Testing
- GDC-0349
- Where
- 2 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- Genentech, Inc.
Advanced Breast Cancer, Metastatic Breast Cancer
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg
This study will assess the relationship between fulvestrant dose and efficacy in postmenopausal women with oestrogen receptor positive advanced breast cancer.
- Trial name
- FINDER II (NCT00313170)
- Testing
- Fulvestrant
- Where
- 34 sites in Belgium, Canada and 6 more
- Volunteers
- 144 people
- Sponsor
- AstraZeneca
Death, Sudden, Cardiac, Out-Of-Hospital Cardiac Arrest
Pre-hospital ECMO in Advanced Resuscitation in Patients With Refractory Cardiac Arrest. ( SUB30 )
To establish whether a pre-hospital advanced physician/ paramedic cardiac arrest team that is ECMO capable can establish ECMO flow within 30 minutes of collapse.
- Conditions
- Death, Sudden, Cardiac, Out-Of-Hospital Cardiac Arrest, Ventricular Fibrillation, Cardiopulmonary Arrest With Successful Resuscitation
- Trial name
- SUB30 (NCT03700125)
- Testing
- ECMO resuscitation
- Where
- 2 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Barts & The London NHS Trust
Esophageal Cancer, Gastric Cancer
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally…
- Trial name
- NCT00005876
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Arterial Occlusive Disease, Intermittent Claudication
ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion
The rise of minimal access surgery has heralded the approval of a number of endovascular devices with similar indications. This is particularly true for the treatment of lower extremity ischemia.
- Trial name
- NCT00407940
- Testing
- Lower extremity Atherectomy and Cryoplasty
- Where
- United States
- Sponsor
- University of California, San Diego
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.